CRISPR THERAPEUTICS AG (CRSP) Total liabilities 2016–2025
CRISPR THERAPEUTICS AG (CRSP) total liabilities at each fiscal year-end, per SEC filings.
$343.4MFY2025 · since FY2016: $112.1M → $343.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $343.4M | +10.8% |
| FY2024 | $310.0M | -10.6% |
| FY2023 | $346.8M | -5.7% |
| FY2022 | $367.6M | +4.3% |
| FY2021 | $352.4M | +115.2% |
| FY2020 | $163.7M | +28.6% |
| FY2019 | $127.3M | +31.5% |
| FY2018 | $96.8M | +15.9% |
| FY2017 | $83.5M | -25.5% |
| FY2016 | $112.1M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice